Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars are finally beginning to exert a greater impact on practice. ASHP’s Biosimilars & Biologics: Implementation and Monitoring in a Healthcare Setting is an authoritative, evidence-based resource that provides an in-depth perspective on all areas related to these innovative drugs.
NOTE: The link below allows you to download the ePub file. If you want the PDF files, click on Table of Contents, browse the chapters by clicking on the drop-down symbol ^, select a chapter, and you will see the DOWNLOAD PDF orange button in the upper right.
Most ePub files can be opened in eBook readers, like the B&N Nook and Kobo eReader. These files have to be converted to .Mobi format before they are usable on the Amazon Kindle device or app.
For your computer, the easiest way to open an ePub file is to double-click on it and let your PC decide which default application should open the file. If no program opens it, then you probably do not have an application installed that can view ePub files. ePub files can also be opened on a computer with various free programs including Adobe Digital Editions.
If you have access to this title you can download the ePub here:
Biosimilars & Biologics (EPUB 4.88 MB)
Biosimilars & Biologics (PDF 3.31 MB)
Get Up to Speed on the Fastest Growing Pharmaceutical Innovation with the Only Guide Written for Pharmacists
Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars are finally beginning to exert a greater impact on practice.
To meet the growing need for information, ASHP has published Biosimilars & Biologics: Implementation and Monitoring in a Healthcare Setting.
This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including:
Legislative/regulatory issues, including the Biosimilars Act and anticipated FDA guidelines
The safety, efficacy, and interchangeability of biologics
The science and analytical chemistry associated with the manufacture of biologics
Needed pharmacovigilance and adverse effect reporting systems
Steven Lucio, PharmD, BCPS
Steven Lucio is Associate Vice President at Vizient, Inc. and formerly served as its Associate Vice President. Prior to joining Vizient, Lucio practiced for almost 10 years within the Baylor Health Care System in various settings, including ICU clinical pharmacy and geriatric ambulatory care. Dr. Lucio earned his Doctor of Pharmacy degree from Creighton University and a Bachelor of Science degree in Pharmacy from the University of Texas at Austin. He is a Board Certified Pharmacotherapy Specialist.
Lucio is lead author of a recently published peer-reviewed article on biosimilars. He is an active speaker and panel moderator and has presented his insight on biosimilars more than a dozen times in the past year.